Gastrointestinal Cancer | Specialty

Role of Immunotherapy in Microsatellite-Stable R/R mCRC

February 25th 2020

Relapsed/Refractory mCRC: Immunotherapy in MSI-High Tumors

February 25th 2020

Management of R/R mCRC: Sequencing for Later-Line Therapies

February 25th 2020

R/R Metastatic CRC: CORRECT, IMblaze370, and ReDOS Trials

February 25th 2020

Third-line and Later-line Therapies in R/R mCRC

February 25th 2020

Role of Rebiopsy and ctDNA Testing at Progression of mCRC

February 25th 2020

Molecular Status and Subsequent Therapies in mCRC

February 25th 2020

Initial Systemic Therapy for Metastatic Colorectal Cancer

February 25th 2020

Continuum of Care in Metastatic Colorectal Cancer

February 25th 2020

Dr. Morris on Treatment Advances Made in BRAF-Mutated mCRC

February 25th 2020

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Dr. Kopetz on the Rationale and Design of the BEACON CRC Study in mCRC

February 22nd 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.

Nivolumab Approved in Japan for Esophageal Cancer

February 21st 2020

The Japanese Ministry of Health, Labor and Welfare has approved nivolumab for the treatment of patients with unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy.

Research Efforts Poised to Redefine Role of Immunotherapy in mCRC

February 21st 2020

Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.

Ongoing Studies May Clarify Role of ADCs in Gastric Cancer and CRC

February 20th 2020

The approval of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers, according to a panel of experts in gastrointestinal malignancies.

Dr. Eng on Increasing Awareness for Adolescents/Young Adults With CRC

February 20th 2020

Cathy Eng, MD, FACP, FASCO, discusses the need to increase awareness regarding treating adolescents and young adults with colorectal cancer.

Emerging Combos Lead to More Questions, Research Efforts in Advanced HCC

February 20th 2020

James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.

Nivolumab/Cabiralizumab Combo Misses PFS Endpoint in Pancreatic Cancer

February 19th 2020

The combination of nivolumab and the investigational CSF-1R inhibitor cabiralizumab with and without chemotherapy did not improve progression-free survival compared with chemotherapy alone in patients with advanced pancreatic cancer, missing the primary endpoint of a phase II trial (NCT03336216).

Immunotherapy Combos Emerging in HCC Armamentarium

February 18th 2020

Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.

Dr. Ilson on Investigative TKI Combinations in Gastric Cancer

February 18th 2020

David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.

Dr. Lockhart on Dual-Immunotherapy Strategies in CRC

February 18th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).